Additional file 1 of The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock

Teixeira, J. Pedro; Perez Ingles, David; Barton, Jordan B.; Dean, James T.; Garcia, Pablo; Kunkel, Susan J.; Sarangarm, Preeyaporn; Weiss, Natalie K.; Schaich, Christopher L.; Busse, Laurence W.; Nielsen, Nathan D.

doi:10.6084/m9.figshare.25397473.v1

13063_2024_7995_MOESM1_ESM.pdf (335.8 kB)

Additional file 1 of The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock

journal contribution

posted on 2024-03-13, 07:00 authored by J. Pedro Teixeira, David Perez Ingles, Jordan B. Barton, James T. Dean, Pablo Garcia, Susan J. Kunkel, Preeyaporn Sarangarm, Natalie K. Weiss, Christopher L. Schaich, Laurence W. Busse, Nathan D. Nielsen

Additional file 1. SPIRIT checklist.

Funding

La Jolla Pharmaceutical Company

History

Usage metrics

Keywords

Septic shock Angiotensin II Vasopressor Renin Biomarker Dipeptidyl-peptidase 3 DPP3

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock

Funding

La Jolla Pharmaceutical Company

History

Usage metrics

Categories

Keywords

Licence

Exports